Price
$30.89
Decreased by -7.60%
Dollar volume (20D)
52.36 M
ADR%
11.04
Shares float
64.51 M
Shares short
9.93 M [15.39%]
Shares outstanding
105.06 M
Market cap
4.12 B
Beta
N/A
Price/earnings
N/A
20D range
30.81 47.40
50D range
24.13 47.40
200D range
12.30 47.40

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases.

It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain.

The company was incorporated in 2022 and is based in New York, New York.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Jul 29, 25 -0.66 -
May 12, 25 -1.03 -1.04
Increased by +0.96%
Mar 26, 25 -3.52 -0.80
Decreased by -340.00%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 25 0.00
Decreased by N/A%
-68.72 M
Decreased by -157.09%
Decreased by N/A%
Decreased by N/A%
Mar 31, 25 0.00
Decreased by N/A%
-76.59 M
Decreased by -285.25%
Decreased by N/A%
Decreased by N/A%
Dec 31, 24 0.00
Decreased by N/A%
-52.87 M
Decreased by -345.38%
Decreased by N/A%
Decreased by N/A%
Sep 30, 24 0.00 - -109.65 M -
Decreased by N/A%
-
Jun 30, 24 0.00 - -26.73 M -
Decreased by N/A%
-
Mar 31, 24 0.00 - -19.88 M -
Decreased by N/A%
-
Dec 31, 23 0.00 - -11.87 M -
Decreased by N/A%
-
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY